Contribution: Industrial Research Assistance Program – Contributions to Firms
Bold Therapeutics Inc.
$1,464,715.00
COVID19 Rapid Response - BOLD-100: A first in class therapeutic for COVID-19
FY 2020-21 · 2020-11-25
Summary
BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of patients with cancer and viral infections, including COVID-19. BOLD-100 has previously been shown to have antiviral activity against SARS-CoV-2 in an vitro model. This project focuses on completing the preclinical data package, preparing for clinical trial in COVID-19, and supporting manufacturing.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
748003712
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-11-25 | 2020-21 | $289,032.00 |
| 3 | 2020-11-25 | 2020-21 | $499,215.00 |
| 4 | 2020-11-25 | 2020-21 | $1,464,715.00 |
| 5 | 2020-11-25 | 2020-21 | $1,464,715.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours.
Agreement End Date
2021-12-31
Agreement Number
961802
Agreement Start Date
2020-11-25
Agreement Title
COVID19 Rapid Response - BOLD-100: A first in class therapeutic for COVID-19
Agreement Title (French)
Réponse rapide face à la COVID-19 - BOLD-100 : Une première dans la classe thérapeutique pour la COVID-19
Agreement Type
Contribution
Agreement Value
$1,464,715.00
Amendment Date
2021-09-27
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of patients with cancer and viral infections, including COVID-19. BOLD-100 has previously been shown to have antiviral activity against SARS-CoV-2 in an vitro model. This project focuses on completing the preclinical data package, preparing for clinical trial in COVID-19, and supporting manufacturing.
Description (French)
BOLD-100 est une thérapie expérimentale en phase clinique, la première de sa catégorie, qui est en cours de développement pour le traitement des patients atteints de cancer et d'infections virales, y compris la COVID-19. BOLD-100 a déjà démontré une activité antivirale contre le SRAS-CoV-2 dans un modèle in vitro. Ce projet se concentre sur l'achèvement de l'ensemble de données précliniques, la préparation de l'essai clinique pour la COVID-19 et le soutien à la fabrication.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Centre
Federal Riding (French)
Vancouver-Centre
Federal Riding Number
59034
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
748003712
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Bold Therapeutics Inc.
Recipient Postal Code
V6C 1E1
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q3-961802
